Allogeneic stem cell transplantation in treatment of chronic myeloid leukaemia – current approach in tyrosine kinase inhibitors era

Lidia Gil; Krzysztof Lewandowski; Mieczysław Komarnicki

doi:10.5114/wo.2010.976

eISSN: 1897-4309
ISSN: 1428-2526

Contemporary Oncology/Współczesna Onkologia

Current issue Archive Manuscripts accepted About the journal Supplements Addendum Special Issues Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures

Editorial System

Submit your Manuscript

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

1/2010
vol. 14

Send email

Copy url:

abstract:

Review paper

Allogeneic stem cell transplantation in treatment of chronic myeloid leukaemia – current approach in tyrosine kinase inhibitors era

Lidia Gil

,

Krzysztof Lewandowski

,

Mieczysław Komarnicki

Współczesna Onkologia (2010) vol. 14; 1 (31–38)

DOI: https://doi.org/10.5114/wo.2010.976

Online publish date: 2010/02/25

View full text Get citation

PlumX metrics:

Introduction of tyrosine kinase inhibitor (TKI), imatinib, revolutionized therapy of chronic myeloid leukemia (CML) and caused considerable reduction in the numbers of allogeneic stem cell transplantation (allo-HSCT) in this disease. Based on current data allo-HSCT remains however the only curative method for CML. Current indication for allo-HSCT in CML are discussed in the paper. Evidence supporting decision concerning transplant procedure (conditioning and source of hematopoietic stem cells), postransplant monitoring on molecular level and treatment of relapse with donor lymphocyte infusion and TKI are presented. Identification of patients with the risk of progression and TKI resistance are an important issue and should be base for decision when and how to perform transplantation.

keywords:

Allogeneic stem cell transplantation in treatment of chronic myeloid leukaemia – current approach in tyrosine kinase inhibitors era

Lidia Gil , Krzysztof Lewandowski , Mieczysław Komarnicki

chronic myeloid leukemia, tyrosine kinase inhibitors, allogeneic stem cell transplantation

Lidia Gil

,

Krzysztof Lewandowski

,

Mieczysław Komarnicki